What is the oncologic risk of stem cell treatment for heart disease?

Konstantinos E. Hatzistergos, Arnon Blum, Tan Ince, James M. Grichnik, Joshua M. Hare

Research output: Contribution to journalReview articlepeer-review

37 Scopus citations

Abstract

Accumulating clinical and preclinical trials are adding to the database, supporting the idea that human cell therapy with MSC transplantation is a safe and a reliable procedure for treating heart disease. Long-term rigorous patient monitoring demonstrates the durability and safety of cell-based therapies for heart disease, with no incidence of tumorigenesis. As with any new therapy, extreme vigilance is required to monitor for, manage, and understand the risk of unwanted and desirable side effects. The specter of neoplasia raises major concerns. However, we conclude that the observations in rodent animal models used to study human diseases should be interpreted with caution when assessing safety and efficacy of any new therapeutic modality and that the risk- benefit profile of MSC cell therapy in the rodent is substantially different from that in large mammals. We believe that ongoing trials of MSCs in humans are of acceptable risk, but strongly argue for ongoing vigilance, particularly over the long term.

Original languageEnglish (US)
Pages (from-to)1300-1303
Number of pages4
JournalCirculation research
Volume108
Issue number11
DOIs
StatePublished - May 27 2011

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'What is the oncologic risk of stem cell treatment for heart disease?'. Together they form a unique fingerprint.

Cite this